Travere Therapeutics Inc (TVTX)

04:19 AM

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

04:19 AM

Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024

Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024

Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024

Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024

Nov 01, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat

Nov 01, 2024

Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024

Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024

Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024

Nov 01, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com

Nov 01, 2024

Nov 01, 2024

Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks

Nov 01, 2024

Oct 31, 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St

Oct 31, 2024

Oct 31, 2024

Travere: Q3 Earnings Snapshot - The Washington Post

Oct 31, 2024

Oct 31, 2024

Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia

Oct 31, 2024

Oct 31, 2024

Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com

Oct 31, 2024

Oct 31, 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024

Oct 30, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com

Oct 30, 2024

Oct 29, 2024

TD Cowen reiterates Buy on Travere shares after PARASOL findings By Investing.com - Investing.com Canada

Oct 29, 2024

Oct 29, 2024

Semanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Oct 29, 2024

Oct 28, 2024

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN - Yahoo Finance

Oct 28, 2024

Oct 27, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Oct 27, 2024

Oct 26, 2024

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - The Manila Times

Oct 26, 2024

Oct 25, 2024

TSX Income Trust Index (RTCM) QuotePress Release - The Globe and Mail

Oct 25, 2024

Oct 25, 2024

(TVTX) Trading Report - Stock Traders Daily

Oct 25, 2024

Oct 24, 2024

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines

Oct 24, 2024

Oct 24, 2024

Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday - MarketBeat

Oct 24, 2024

Oct 24, 2024

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money' - Yahoo Finance

Oct 24, 2024

Oct 23, 2024

Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High? - MSN

Oct 23, 2024

Oct 21, 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results - The Manila Times

Oct 21, 2024

Oct 21, 2024

Travere Therapeutics (NASDAQ:TVTX) Shares Gap UpTime to Buy? - MarketBeat

Oct 21, 2024

Oct 21, 2024

Travere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & Company - MarketBeat

Oct 21, 2024

Oct 21, 2024

Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) - Benzinga

Oct 21, 2024

Oct 21, 2024

Wells Fargo raises Travere Therapeutics stock to Overweight rating By Investing.com - Investing.com Canada

Oct 21, 2024

Oct 18, 2024

State Street Corp's Strategic Reduction in Travere Therapeutics Holdings - GuruFocus.com

Oct 18, 2024

Oct 18, 2024

TVTX stock soars to 52-week high, hits $18.63 amid robust gains - Investing.com Australia

Oct 18, 2024

Oct 17, 2024

Travere Therapeutics (NASDAQ:TVTX) Hits New 1-Year HighHere's Why - MarketBeat

Oct 17, 2024

Oct 17, 2024

TVTX stock soars to 52-week high, hits $18.63 amid robust gains By Investing.com - Investing.com South Africa

Oct 17, 2024

Oct 17, 2024

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy - StockTitan

Oct 17, 2024

Oct 17, 2024

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PR Newswire

Oct 17, 2024

Oct 16, 2024

Breaking Down Travere Therapeutics: 23 Analysts Share Their Views - Benzinga

Oct 16, 2024

Oct 16, 2024

Travere Therapeutics (NASDAQ:TVTX) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat

Oct 16, 2024

Oct 16, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 16, 2024

Oct 15, 2024

Investing in Travere Therapeutics Inc (TVTX) Is Getting More Attractive - Knox Daily

Oct 15, 2024

Oct 15, 2024

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 - The Manila Times

Oct 15, 2024

Oct 15, 2024

Travere Awaits FDA Ruling On Rare Kidney Disease Drug - RTTNews

Oct 15, 2024